Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb’s (NYSE: BMY) fair price estimate based on expected 2019 earnings is $59, according to Trefis estimates. This is in line with the current market price of around $58.

What’s Bristol-Myers Squibb’s Fair Stock Price Estimate Based On Expected 2019 Earnings?

GlaxoSmithKline

Merck

Novo Nordisk

Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

4 Big Drugmakers to Bet on After a Great Earnings Season

Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of liver cancer, makes progress.

Bristol-Myers' Opdivo/Yervoy sBLA for HCC Gets Priority Review

Celgene

Good news for Celgene is good news for Bristol-Myers Squibb -- and investors who like the big drugmaker's juicy dividend.

Why Celgene's Latest FDA Approval Makes Bristol-Myers Squibb's Dividend Look Even Better

Shares of Nektar Therapeutics popped Monday after the biotech company's Bristol-Myers Squibb-partnered regimen in never-before-treatment melanoma patients continued to show promise.
The post Can This Biotech Improve On Bristol-Myers' Blockbuster Cancer Drug?

Can This Biotech Improve On Bristol-Myers' Blockbuster Cancer Drug?

Is Bristol's stock still an attractive buy after last month's uptick?

Why Bristol-Myers Squibb Stock Gained 13% in October

Apple

Amazon

Cisco Systems

Ford Motor Company

Alphabet

Microsoft

Oracle

Several companies, including Microsoft, Berkshire Hathaway, Alphabet and Apple are sitting on more than $100 billion dollars of cash, which is leading some on Wall Street to question why America's largest companies aren't spending.

Here are the 10 companies with the most cash on hand

While the results are promising, are they enough to threaten Merck's cancer superdrug Keytruda?

Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?

AbbVie

Brinker International

Group 1 Automotive

Hewlett Packard

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

5 High-Flying Stocks Near 52-Week High That Can Scale Higher.

Celgene and Bristol-Myers Squibb up around 1%

2 Health Stocks With Gains Thursday

Bristol-Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Bristol-Myers (BMY) Hits Fresh High: Is There Still Room to Run?

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q3 2019 Results - Earnings Call Transcript

Opdivo didn't turn in an impressive performance, but BMS' other drugs generated more than enough growth to top Wall Street's estimates.

Bristol-Myers Squibb Beats Expectations in Q3 as Its Celgene Acquisition Nears the Finish Line

Bristol-Myers (BMY) beats both earnings and sales estimates in the third quarter, primarily on robust sales of Eliquis and Sprycel.

Bristol-Myers' (BMY) Q3 Earnings & Revenues Beat Estimates

Dunkin' Brands

More economic morsels in today's pre-market activity, along with a continued deluge of new quarterly earnings reports, continue one of the busiest weeks for Q3 earnings season.

Claims, Income, Spending & Q3 Earnings: A Full Plate

Bristol-Myers Squibb (NYSE: BMY) reported third-quarter earnings of $1.17 per share Thursday, beating the analyst consensus estimate of $1.07.

Bristol-Myers Squibb Posts Q3 Earnings Beat, Raises Full-Year Guidance

Drug giants Bristol-Myers Squibb and Celgene topped third-quarter expectations Thursday, but shares slipped. In premarket trading on the stock market today, BMY stock skidded 1.4%.

Drug Giants Bristol-Myers, Celgene Top Third-Quarter Estimates

Bristol-Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Bristol-Myers (BMY) Rating Upgrade to Buy

Bristol-Myers (BMY) delivered earnings and revenue surprises of 10.38% and 3.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Bristol-Myers Squibb (BMY) Q3 Earnings and Revenues Top Estimates

U.S. drugmaker Bristol-Myers Squibb Co  reported higher-than-expected third-quarter profit on Thursday, helped by strong sales of blood thinner Eliquis, even as growth of its blockbuster cancer treatment Opdivo slowed.

Bristol-Myers posts better-than-expected results, Opdivo growth slows

Bristol-Myers Squibb Co. shares BMY, +1.97% rose 0.9% after the company beat earnings estimates but lowered its full-year per-share earnings guidance.

Bristol-Myers tops earnings estimates but lowers guidance

There has been much debate whether it is best to hold shares in Celgene or Bristol-Myers.

Sell Celgene, Buy Bristol-Myers: Counting The Profits At The Halfway Mark

Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Bristol-Myers (BMY) Ahead of Earnings?

Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.

Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q3 Earnings?

Investors will focus on regular top and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.

News for Bristol-Myers Stock (BMY)